Number of qualified people: CDEC mentioned the uncertainty in the volume of people with reasonably extreme to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some sufferers that are labeled as having mild or average ailment can have a severe bleeding phenotype, https://hemgenix37182.blogpostie.com/57220430/hemgenix-fundamentals-explained